GlaxoSmithKline, the world’s largest vaccine maker, said the global push to develop an immunisation against the coronavirus would not lead to widely available products before the second half of next year. “If things go right ... to get to scale of manufacturing in the hundreds of millions (of doses) is going to be in the second half of next year,” CEO Emma Walmsley told a media briefing after the release of first-quarter results. This would require swift progress in global development efforts to show an experimental vaccine is safe, effective and dosed in the right way, she added.